EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Serum Galectin-3 in Hepatitis C Virus Infection Declines after Successful Virus Eradication by Direct-Acting Antiviral Therapy

Kilian Weigand, Georg Peschel, Jonathan Grimm, Martina Müller, Christa Buechler

Journal of Gastrointestinal and Liver Diseases · 17.12.2022 · 31 (4) · 444-452

DOI: 10.15403/jgld-4341 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastrointestinal and Liver Diseases, online erschienen am 17.12.2022. Verfasst von Kilian Weigand und 4 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine I Department, Gastroenterology, Hepatology, Endocrinology, Rheumatology and In-fectious Diseases, University Hospital Regensburg, R…. Hauptthemen laut MEDLINE: Antiviral Agents, Galectin 3, Hepatitis C, Chronic. Die Arbeit wurde bisher 10-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims: Serum galectin-3 is regarded as an inflammatory marker in patients with chronic liver diseases. Hepatitis C virus (HCV) infection is associated with higher levels of inflammatory molecules which ameliorate by efficient treatment with direct-acting antivirals (DAAs). The aim of this study was to compare serum galectin-3 levels between HCV patients before treatment with DAAs and at the time of sustained virologic response at 12 weeks post-treatment (SVR12).

Methods

Hepatitis B and human immunodeficiency virus-negative HCV infected patients not treated with HCV therapies before were recruited at the University Hospital of Regensburg. Galectin-3 was measured by enzyme-linked immunosorbent assay in the serum of patients with chronic HCV infection, before treatment initializing, at four and twelve weeks after the start of DAA therapy and at SVR12. Associations of serum galectin-3 with C-reactive protein (CRP), leukocyte count and measures of liver disease severity were analyzed. Liver fibrosis was assessed by acoustic radiation force impulse, the aspartate aminotransferase/platelet ratio index, and the fibrosis-4 score.

Results

In the serum of 81 HCV patients, galectin-3 did not correlate with viral load, viral genotype, CRP, leukocyte count, or the model for end stage liver disease score. Therapy with DAAs effectively diminished viral load within four weeks in all patients. The median value of the serum galectin-3 was 3.0 (Q1:2.0, Q3:4.0) ng/ml before therapy and declined to 2.4 (Q1: 1.7, Q3: 3.4) ng/ml at SVR12 (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsGalectin 3Hepatitis C, ChronicHumansHepacivirusLiver CirrhosisSeverity of Illness IndexSustained Virologic ResponseTreatment Outcome

Substanzen

Antiviral AgentsGalectin 3

Autor:innen und Institutionen

  • Internal Medicine I Department, Gastroenterology, Hepatology, Endocrinology, Rheumatology and In-fectious Diseases, University Hospital Regensburg, Regensburg; Gastroenterology Department, Gemeinschaftsklinikum Mittelrh…
  • Internal Medicine I Department, Gastroenterology, Hepatology, Endocrinology, Rheumatology and In-fectious Diseases, University Hospital Regensburg, Regensburg; Internal Medicine Department, Klinikum Fürstenfeldbruck, 82…
  • Internal Medicine I Department, Gastroenterology, Hepatology, Endocrinology, Rheumatology and In-fectious Diseases, University Hospital Regensburg, Regensburg, Germany. jonathan.grimm@stud.uni-regensburg.de.
  • Internal Medicine I Department, Gastroenterology, Hepatology, Endocrinology, Rheumatology and In-fectious Diseases, University Hospital Regensburg, Regensburg, Germany. martina.mueller-schilling@klinik.uni-regensburg.de.
  • Internal Medicine I Department, Gastroenterology, Hepatology, Endocrinology, Rheumatology and In-fectious Diseases, University Hospital Regensburg, Regensburg, Germany. christa.buechler@ukr.de.

Zitieren

APA

Weigand, K., Peschel, G., Grimm, J., Müller, M., & Buechler, C. (2022). Serum Galectin-3 in Hepatitis C Virus Infection Declines after Successful Virus Eradication by Direct-Acting Antiviral Therapy. Journal of Gastrointestinal and Liver Diseases, 31(4), 444-452. https://doi.org/10.15403/jgld-4341

Vancouver

Weigand K, Peschel G, Grimm J, Müller M, Buechler C. Serum Galectin-3 in Hepatitis C Virus Infection Declines after Successful Virus Eradication by Direct-Acting Antiviral Therapy. Journal of Gastrointestinal and Liver Diseases. 2022;31(4):444-452. doi:10.15403/jgld-4341

BibTeX
@article{Weigand2022,
  author = {Weigand, Kilian and Peschel, Georg and Grimm, Jonathan and Müller, Martina and Buechler, Christa},
  title = {Serum Galectin-3 in Hepatitis C Virus Infection Declines after Successful Virus Eradication by Direct-Acting Antiviral Therapy},
  journal = {Journal of Gastrointestinal and Liver Diseases},
  year = {2022},
  volume = {31},
  number = {4},
  pages = {444--452},
  doi = {10.15403/jgld-4341}
}
Kostenlos starten →